erlotinib + etoposide
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent or Refractory Pediatric Ependymoma
Conditions
Recurrent or Refractory Pediatric Ependymoma
Trial Timeline
Sep 27, 2010 → Nov 26, 2012
NCT ID
NCT01032070About erlotinib + etoposide
erlotinib + etoposide is a phase 2 stage product being developed by Astellas Pharma for Recurrent or Refractory Pediatric Ependymoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01032070. Target conditions include Recurrent or Refractory Pediatric Ependymoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01032070 | Phase 2 | Terminated |
Competing Products
20 competing products in Recurrent or Refractory Pediatric Ependymoma